News | PET-CT | June 12, 2017

Philips Highlights the Value of Advanced Molecular Imaging at SNMMI 2017

Showcases continued commitment to creating innovative solutions that enhance and simplify the clinical decision making path, from diagnosis to treatment, to drive more personalized care

PET/CT

Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation and more personalized care at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 Annual Meeting. Molecular imaging provides insight into molecular and cellular processes in the body, and has the potential to transform healthcare by offering earlier detection and more precise treatment of diseases. Philips continues to bring solutions into the field of nuclear medicine that enhance quantitative accuracy and enable new clinical applications driving more personalized care and workflow efficiencies from diagnosis to treatment.

Nuclear medicine technology has significantly evolved over the years – growing from just scanners to solutions that comprise systems and advanced informatics, for enhanced image quality, quantification and analytics. As value-based care changes the way healthcare organizations approach care delivery, there is a greater need for easy to use, fast and precise imaging. With increased access to better data, clinicians are looking for ways to make that data actionable, especially in terms of customizing patient treatment. Molecular imaging accomplishes that, allowing physicians to make decisions based on the specific molecular and cellular patterns of disease in addition to the patient’s anatomy. 

“Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care,” said Kirill Shalyaev, Ph.D., Business Leader, Advanced Molecular Imaging, Philips. “Philips has made a lasting impact in nuclear medicine by providing clinicians with innovations such as Time-of-Flight PET and digital PET/CT, and we remain dedicated to developing solutions that simplify the path to clinical decision making for more confident diagnosis and a faster path to treatment.”

Even with its significant growth in past years, the opportunity for further innovation and growth in nuclear medicine remains, continuing to maximize its value and impact. The latest solutions from Philips include:

Vereos Digital PET/CT – A fully digital PET/CT system featuring Philips proprietary Digital Photon Counting (DPC) technology. Vereos offers improved detectability and characterization of small lesions. The system provides uncompromised detectability and quantification at half the PET dose. Vereos also provides lesion detectability in one tenth of the time. 

Ingenuity TF PET/CT – Leverages Philips’ Astonish TF technology for enhanced image contrast, resolution, and quality. Features Philips’ proprietary xPand5 quantification tools to assist in measuring and monitoring disease progression. These technologies join CT advances, such as iPatient, iDose⁴ and metal artifact reduction for implants (O-MAR), to drive confidence and consistency through personalized patient centric workflow.

IntelliSpace Portal 9.0 – IntelliSpace Portal 9.0 – The latest edition of Philips’ comprehensive, advanced visualization and analysis platform offers quantitative tumor tracking and treatment response tools with a streamlined workflow for follow‐up and analysis in oncology cases. IntelliSpace Portal 9.0 provides enterprise‐wide access to a comprehensive suite of Molecular Imaging processing and review applications for general Nuclear Medicine, SPECT, SPECT/CT and PET/CT.

SPECT Solutions – To fulfill the need for clinically dependable SPECT systems, Philips provides cost-efficient cardiac and general-purpose SPECT solutions that maximize the return on investment.

For more information: www.philips.com 

Related Content

Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
Wake Radiology Launches First Installation of EnvoyAI Platform
News | Artificial Intelligence | June 13, 2018
Artificial intelligence (AI) platform provider EnvoyAI recently completed their first successful customer installation...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
American Society of Neuroradiology Honors Peter Chang with Cornelius G. Dyke Memorial Award
News | Neuro Imaging | June 13, 2018
Peter Chang, M.D., current neuroradiology fellow at UCSF and recently recruited co-director of the UCI Center for...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Zebra Medical Vision Unveils AI-Based Chest X-ray Research
News | Artificial Intelligence | June 08, 2018
June 8, 2018 — Zebra Medical Vision unveiled its Textray chest X-ray research, which will form the basis for a future
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Vinay Vaidya, Chief Medical Information Officer at Phoenix Children’s Hospital

Vinay Vaidya, Chief Medical Information Officer at Phoenix Children’s Hospital

Sponsored Content | Case Study | Artificial Intelligence | June 05, 2018
The power to predict a cardiac arrest, support a clinical diagnosis or nudge a provider when it is time to issue medi
Videos | Patient Engagement | June 04, 2018
At SIIM 2018, Alexander J. Towbin, M.D., Radiologist, Department of Radiology and Medical Imaging, Neil D. Johnson...
Intelerad Launches AI Initiative for Imaging Workflow Intelligence and Analytics
News | Artificial Intelligence | May 29, 2018
Intelerad Medical Systems announced the launch of its artificial intelligence (AI) initiative along with the expansion...
Overlay Init